Contract Services Pre-Clinical Outsourcing
Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress
The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...
August 25, 2025 | Company results
WuXi XDC Delivers 62% Revenue Growth and Record Project Momentum in H1 2025
- Revenue increased by 62.2% YoY to RMB 2,701 million - Gross profit surged by 82.2% YoY to RMB 975 million, with i...
August 19, 2025 | Company results
WuXi Biologics Achieves Fully Automated Continuous Drug Substance Manufacturing at Pilot Scale with WuXiUP™ Platform
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the ...
August 13, 2025 | News
PolyActiva Launches U.S. Trial of Glaucoma Implant Following Australia Success
PA5108, a new chemical entity, is an investigational, biodegradable ocular micro implant, designed to deliver sustained intraocular pressure control for ...
August 08, 2025 | News
Bridging Real-World Evidence and AI: Unlocking Smarter, Faster Clinical Research in Asia
Having worked with pharma clients, healthcare providers, and digital platforms across the Asia-Pacific region, I’ve seen the challenges first-hand&md...
August 04, 2025 | Opinion
I Peace and Vita Therapeutics Partner to Develop Universal Hypoimmune iPSC Lines for Cell Therapy
Leading GMP cell CDMO I Peace, Inc. specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the co...
July 11, 2025 | News
WuXi Biologics Launches WuXiHigh™2.0 to Enable Record-Setting High-Concentration Biologic Formulations
The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces visc...
July 01, 2025 | News
Porton Advanced Supports IND Approval of Tasly’s Dual-Targeting CAR-T Therapy for Recurrent Glioblastoma
Porton Advanced proudly announces its CDMO support for Tasly Pharmaceutical Co., Ltd.'s innovative CAR-T therapy, "P134 Cell Injection," which has received...
April 17, 2025 | News
TCI Biotech Elevates CDMO+ Services with US-Based Glass Bottling for Liquid Supplements
TCI Biotech (TCI Co., Ltd.), a CDMO+ organization specializing in health and wellness products, is spotlighting its comprehensive US-based glass bottling s...
April 03, 2025 | News
Chance Pharmaceuticals Secures New Funding to Advance Phase III Trials for CXG87 and Expand Inhalation Therapy Pipeline
Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapi...
March 18, 2025 | News
WuXi Biologics Introduces EffiX™ a High-Yield E. coli Expression Platform for Recombinant Proteins and Plasmid DNA Production
EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. ...
March 04, 2025 | News
Eleva and 3PBIOVIAN Forge Strategic Alliance to Advance Clinical-Grade Biologics Production
3PBIOVIAN provides production capacity for clinical-grade material for current and future development programs including Eleva’s proprietary Factor...
February 05, 2025 | News
SN BioScience Secures FDA IND Clearance for SNB-101 Phase 1b/2 Trial, Targeting Extensive Stage Small Cell Lung Cancer
SN BioScience announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administra...
January 13, 2025 | News
Regor’s Oral GLP-1RA RGT-075 Shows 5% Placebo-Adjusted Weight Loss in Phase 2a Trial with Strong Safety Profile
Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no ...
January 13, 2025 | News
Most Read
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
